Ligand Pharma Swings to Profit on Soaring Revenue, Strategic Investments

TL;DR

**LGND is back in the black with massive revenue growth and smart investments, making it a strong buy for long-term gains.**

AI Summary

LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported a significant turnaround for the quarter ended September 30, 2025, with net income soaring to $117.27 million, a substantial increase from a net loss of $7.17 million in Q3 2024. Total revenues and other income more than doubled to $115.46 million from $51.81 million in the prior year's quarter, driven by a robust 51.2% increase in royalties to $46.59 million and a massive jump in contract revenue and other income to $58.20 million from $13.85 million. Research and development expenses increased significantly to $21.02 million from $5.68 million, and general and administrative expenses rose to $28.45 million from $24.48 million. The company also recorded a substantial gain of $75.89 million from changes in fair value of equity-method investments and other investments, compared to a loss of $3.03 million in Q3 2024. Cash and cash equivalents increased to $139.38 million as of September 30, 2025, up from $72.31 million at December 31, 2024, largely due to $419.89 million in net cash provided by financing activities, including $460.00 million from the issuance of 2030 Convertible Senior Notes.

Why It Matters

This strong performance signals a significant shift for Ligand, demonstrating the effectiveness of its financing and licensing model. The substantial increase in net income and revenue, particularly from royalties and contract revenue, indicates successful pipeline development and commercialization efforts, which could attract new institutional investors. For employees, this growth could mean increased job security and potential for expansion. Customers benefit from the continued development of high-value medicines. In a competitive biopharmaceutical landscape, Ligand's ability to generate substantial non-operating income from investments, alongside core royalty growth, positions it favorably against peers reliant solely on product sales.

Risk Assessment

Risk Level: medium — While net income is up significantly, the company's operating cash flow for the nine months ended September 30, 2025, was only $3.44 million, a sharp decline from $68.58 million in the prior year. This suggests that a substantial portion of the reported net income is driven by non-cash gains, such as the $75.89 million gain from fair value adjustments of investments, rather than core operational strength. Additionally, the significant increase in R&D expenses to $77.67 million for the nine months ended September 30, 2025, from $17.00 million in the prior year, while potentially beneficial long-term, represents a substantial cash outlay.

Analyst Insight

Investors should scrutinize the quality of earnings, noting the heavy reliance on non-operating gains for the net income surge. While the revenue growth is positive, a deeper dive into the sustainability of operating cash flow is warranted. Consider LGND for long-term growth, but be aware of potential volatility tied to investment valuations and high R&D spend.

Financial Highlights

debt To Equity

0.54

revenue

$115.46M

operating Margin

N/A

total Assets

$1,476.77M

total Debt

$445.49M

net Income

$117.27M

eps

$6.07

gross Margin

N/A

cash Position

$139.38M

revenue Growth

+122.9%

Revenue Breakdown

Key Numbers

• $117.27M — Net Income (Increased from a net loss of $7.17M in Q3 2024)
• $115.46M — Total Revenues and Other Income (Increased from $51.81M in Q3 2024)
• $46.59M — Royalties (Increased from $31.71M in Q3 2024, a 51.2% rise)
• $58.20M — Contract Revenue and Other Income (Increased from $13.85M in Q3 2024)
• $75.89M — Gain from change in fair value of equity-method investments and other investments (Compared to a loss of $3.03M in Q3 2024)
• $21.02M — Research and Development Expenses (Q3 2025) (Increased from $5.68M in Q3 2024)
• $77.67M — Research and Development Expenses (9 months 2025) (Increased from $17.00M in 9 months 2024)
• $139.38M — Cash and Cash Equivalents (As of September 30, 2025, up from $72.31M at December 31, 2024)
• $419.89M — Net cash provided by financing activities (For the nine months ended September 30, 2025)
• $460.00M — Gross proceeds from issuance of 2030 Convertible Senior Notes (For the nine months ended September 30, 2025)

Key Players & Entities

• LIGAND PHARMACEUTICALS INCORPORATED (company) — registrant
• Todd Davis (person) — Chief Executive Officer and Chief Operating Decision Maker
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Market (market) — exchange where common stock is registered
• CyDex Pharmaceuticals, Inc. (company) — subsidiary
• Palvella Therapeutics, Inc. (company) — partner company
• Viking Therapeutics, Inc. (company) — partner company
• Takeda Pharmaceutical Company Limited (company) — partner company
• Travere Therapeutics, Inc. (company) — partner company
• Apeiron Acquisition (company) — acquisition target in 2024

FAQ

Risk Factors

• Fair Value Fluctuations of Investments [medium — financial]: The company recorded a substantial gain of $75.89 million from changes in fair value of equity-method and other investments in Q3 2025, compared to a loss of $3.03 million in Q3 2024. Significant fluctuations in the fair value of these investments introduce volatility to earnings.
• Increased R&D Spending [medium — operational]: Research and development expenses surged to $21.02 million in Q3 2025 from $5.68 million in Q3 2024, and $77.67 million for the nine months ended September 30, 2025, up from $17.00 million in the prior year period. This significant increase in R&D investment may impact near-term profitability.
• Rising General and Administrative Expenses [low — operational]: General and administrative expenses increased to $28.45 million in Q3 2025 from $24.48 million in Q3 2024. While not as dramatic as R&D, this trend warrants monitoring for its impact on operating leverage.
• Reliance on Financing Activities [medium — financial]: The company raised $460.00 million from the issuance of 2030 Convertible Senior Notes, contributing significantly to the $419.89 million net cash provided by financing activities for the nine months ended September 30, 2025. Future debt obligations and interest payments associated with these notes represent a financial commitment.
• Biopharmaceutical Industry Regulations [high — regulatory]: As a biopharmaceutical company, Ligand is subject to extensive regulatory oversight from bodies like the FDA. Changes in regulations, approval processes, or compliance requirements could impact product development and market access.
• Competition and Market Dynamics [medium — market]: The biopharmaceutical industry is highly competitive. The success of Ligand's partners' products, which drive Ligand's revenue, depends on their ability to compete effectively against other therapies and navigate evolving market demands.

Industry Context

Ligand Pharmaceuticals operates in the biopharmaceutical sector, focusing on enabling scientific advancement through financing and licensing. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success is often driven by strategic partnerships and the ability to identify and support promising drug candidates.

Regulatory Implications

As a biopharmaceutical company, Ligand is indirectly subject to the regulatory landscape governing its partners' drug development and commercialization. Any changes in FDA or other global regulatory body requirements for drug approval, manufacturing, or post-market surveillance could impact the success of its partners and, consequently, Ligand's royalty and contract revenues.

What Investors Should Do

1. Monitor R&D and G&A expense trends
2. Analyze the drivers of 'Contract Revenue and Other Income'
3. Evaluate the impact of convertible note issuance
4. Assess the volatility from investment fair value changes

Key Dates

• 2025-09-30: Quarter ended September 30, 2025 — Reported a significant turnaround with net income of $117.27 million and total revenues more than doubling.
• 2025-09-30: Nine months ended September 30, 2025 — Raised $460.00 million from 2030 Convertible Senior Notes, bolstering cash position.
• 2024-12-31: As of December 31, 2024 — Company had $72.31 million in cash and cash equivalents prior to the significant financing activities in 2025.
• 2024-09-30: Quarter ended September 30, 2024 — Reported a net loss of $7.17 million and total revenues of $51.81 million, providing a baseline for the Q3 2025 improvement.

Glossary

Equity-method investments

Investments where the investor has significant influence over the investee's operating and financial policies, typically holding between 20% and 50% of the voting stock. (Changes in the fair value of these investments can significantly impact the company's reported net income, as seen in Q3 2025.)

Convertible Senior Notes

Debt securities that can be converted into a predetermined amount of the issuer's equity at certain times during their life. (Ligand issued $460.00 million in 2030 Convertible Senior Notes, impacting its capital structure and future obligations.)

Captisol

A specific technology or product offered by Ligand, contributing to its revenue stream. (Captisol revenue showed a significant increase of 70.1% in Q3 2025, highlighting its growing importance.)

Financial royalty assets

Assets that represent a right to receive future royalty payments, often structured as a financial instrument. (Income from these assets grew by 24.6% in Q3 2025, contributing to overall revenue growth.)

Intangible assets, net

Non-physical assets such as patents, trademarks, and licenses, net of accumulated amortization. (The company's intangible assets decreased from $266.65 million to $233.54 million, likely due to amortization.)

Year-Over-Year Comparison

Ligand Pharmaceuticals has demonstrated a remarkable turnaround in Q3 2025 compared to Q3 2024. Total revenues and other income more than doubled, driven by substantial growth in royalties and contract revenue. Net income shifted from a significant loss to a strong profit. While R&D expenses have increased substantially, this is offset by the robust top-line growth and a significant positive swing in investment fair value changes, leading to a much stronger financial position.

Key Financial Figures

• $0.001 — ch registered: Common Stock, par value $0.001 per share LGND The Nasdaq Global Marke

Filing Documents

• lgnd-20250930.htm (10-Q) — 1566KB
• exhibit191_insidertradingc.htm (EX-19.1) — 103KB
• lgnd_93025exhibit311.htm (EX-31.1) — 15KB
• lgnd_93025exhibit312.htm (EX-31.2) — 15KB
• lgnd_93025exhibit321.htm (EX-32.1) — 11KB
• lgnd-20250930_g1.jpg (GRAPHIC) — 43KB
• 0000886163-25-000063.txt ( ) — 10141KB
• lgnd-20250930.xsd (EX-101.SCH) — 68KB
• lgnd-20250930_cal.xml (EX-101.CAL) — 110KB
• lgnd-20250930_def.xml (EX-101.DEF) — 471KB
• lgnd-20250930_lab.xml (EX-101.LAB) — 925KB
• lgnd-20250930_pre.xml (EX-101.PRE) — 659KB
• lgnd-20250930_htm.xml (XML) — 1401KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (unaudited)

ITEM 1. Condensed Consolidated Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations 5 Condensed Consolidated Statements of Comprehensive Income (Loss) 6 Condensed Consolidated Statements of Stockholders ' Equity 7 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 11

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 35

Quantitative and Qualitative Disclosures about Market Risk

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 43

Controls and Procedures

ITEM 4. Controls and Procedures 43

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

ITEM 1. Legal Proceedings 44

Risk Factors

ITEM 1A. Risk Factors 45

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 45

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities 45

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures 45

Other Information

ITEM 5. Other Information 45

Exhibits

ITEM 6. Exhibits 48 SIGNATURE 48 2 GLOSSARY OF TERMS AND ABBREVIATIONS Abbreviation Definition 2024 Annual Report Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 28, 2025 ASC Accounting Standards Codification ASU Accounting Standards Update Company Ligand Pharmaceuticals Incorporated, including subsidiaries CVR Contingent value right CyDex CyDex Pharmaceuticals, Inc. ESPP Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan, as amended and restated, effective June 6, 2019 FASB Financial Accounting Standards Board FDA Food and Drug Administration GAAP Generally accepted accounting principles in the United States Ligand Ligand Pharmaceuticals Incorporated, including subsidiaries Metabasis Metabasis Therapeutics, Inc. NDA New Drug Application Palvella Palvella Therapeutics, Inc. Q3 2024 The Company's fiscal quarter ended September 30, 2024 Q3 2025 The Company's fiscal quarter ended September 30, 2025 SBC Share-based compensation expense SEC Securities and Exchange Commission Takeda Takeda Pharmaceutical Company Limited Travere Travere Therapeutics, Inc. Viking Viking Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements : You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discuss

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements LIGAND PHARMACEUTICALS INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except par value) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 139,376 $ 72,307 Short-term investments 525,146 183,858 Accounts receivable, net 57,560 38,376 Inventory 11,900 14,114 Short-term portion of financial royalty assets, net 12,416 10,025 Income taxes receivable 536 4,073 Other current assets 6,986 8,806 Total current assets 753,920 331,559 Intangible assets, net 233,535 266,648 Goodwill 101,541 105,250 Long-term portion of financial royalty assets, net 206,332 185,024 Noncurrent derivative assets 9,351 10,583 Property and equipment, net 3,466 15,133 Lease right-of-use assets 7,609 9,673 Equity method investments 42,000 — Other investments 106,721 10,908 Deferred income taxes, net 9,526 72 Other assets 2,771 6,924 Total assets $ 1,476,772 $ 941,774 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,679 $ 5,233 Accrued liabilities 24,084 27,906 Income taxes payable 1,284 1,199 Current contingent liabilities 268 206 Current operating lease liabilities 1,089 1,266 Other current liabilities 135 1,302 Total current liabilities 30,539 37,112 Long-term deferred revenue — 2,246 Long-term contingent liabilities 3,569 3,475 Long-term operating lease liabilities 4,415 5,815 Long-term portion of 2030 convertible senior notes, net 445,493 — Deferred income taxes, net 22,673 32,524 Other long-term liabilities 19,912 30,163 Total liabilities 526,601 111,335 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000 shares authorized; zero issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 60,000 shares authorized; 19,656 and 19,106 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively

Business

Business We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. Basis of Presentation and Principles of Consolidation Our unaudited condensed consolidated financial statements include the financial statements of Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. We have included all adjustments, consisting only of normal recurring adjustments, which we considered necessary for a fair presentation of our financial results. These unaudited condensed consolidated financial statements and accompanying notes should be read together with the audited consolidated financial statements included in our 2024 Annual Report. Interim financial results are not necessarily indicative of the results that may be expected for the full year. Segment Information The Company has one operating and one reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker ("CODM") is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. The CODM does not evaluate, manage or measure performance of segments using asset information. The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below: Three months ended Nine months ended September 30, September 30, 2025 2024 2025 2024 Total revenu

View Full Filing

View this 10-Q filing on SEC EDGAR